Druckschmerzhafte Körperstellen – Enthesitis?

H. Haibel

doi:10.1055/s-0038-1660907

Arthritis und Rheuma, Inhaltsverzeichnis

Arthritis und Rheuma 2018; 38(03): 176-184
DOI: 10.1055/s-0038-1660907

Rheuma – vom Symptom zur Diagnose

Schattauer GmbH

Druckschmerzhafte Körperstellen – Enthesitis?

Points tender to pressure – enthesitis?

Authors

H. Haibel

¹Rheumatologie, Charité Campus Benjamin Franklin, Berlin, Deutschland

Abstract

Zusammenfassung

Die Enthesitis ist eine häufige Manifestation bei Spondyloarthritiden (SpA) und Psoriasis- Arthritis (PsA) und tritt bei bis zu 40 % der Patienten mit SpA auf. Wegen ihrer pathognomonischen Bedeutung ist Enthesitis in verschiedenen Klassifikationskriterien für SpA und PsA als ein Eingangs- oder Nebenkriterium aufgenommen worden. Häufigste Lokalisation ist die Ferse, aber Enthesitiden können ubiquitär an Sehnenansätzen in den Knochen auftreten. Bei der Diagnose der Enthesitis sind zahlreiche Differenzialdiagnosen zu beachten, insbesondere sollten mechanisch-degenerative Ursachen unterschieden und eine Fibromyalgie ausgeschlossen werden. Als bildgebende Verfahren sind der Power Doppler Ultraschall (PDUS) und die Magnetresonanztomografie (MRT) besonders diagnostisch hilfreich. Die therapeutischen Optionen bei Enthesitis sind begrenzt. Es werden die Gabe von nichtsteroidalen Antirheumatika und lokale Steroidinjektionen empfohlen. Während in kleineren Studien für Disease Modifying Antirheumatic Drugs keine Wirksamkeit gezeigt werden konnte, haben sich TNF-alpha-Blocker, Anti-IL-17-, Anti-IL-12/23- sowie Anti-IL-23-Antikörper in randomisierten kontrollierten Studien sowohl bei SpA als auch/oder bei PsA als effektiv erwiesen. Sie sind jedoch derzeit nicht für die Therapie einer alleinig vorliegenden Enthesitis zugelassen.

Summary

Enthesitis is a frequent manifestation in spondyloarthritides (SpA) and psoriatic arthritis (PsA) and can be found in up to 40 % of patients with SpA. Because of the pathognomonic relevance the classification criteria for SpA and PsA are using enthesitis as entrance- or secondary criterion. Enthesitis is most frequently localized at the heel but it can occur at any insertion of an enthesis into the bone. When diagnosing enthesitis differential diagnoses should be considered, especially mechanic-degenerative causes and fibromyalgia should be excluded. The imaging techniques power Doppler ultrasound (PDUS) and Magnetic Resonance Imaging (MRI) are most helpful in making the diagnosis. The therapeutic options for enthesitis are limited. Nonsteroidal antirheumatic drugs and local injections of corticosteroids are recommended to use. In small clinical trials no efficacy of disease-modifying antirheumatic drugs could be demonstrated. In contrast, TNF alpha blockers Anti-IL-17- and Anti-IL-12/23 as well as Anti-IL-23-antibodies were shown to be highly effective in randomized controlled trials in SpA and/or PsA, but for enthesitis only, currently they are not approved.

Schlüsselwörter

Spondyloarthritis - Enthesitis - Enthesiopathie - Psoriasis-Arthritis - ankylosierende Spondylitis

Keywords

Spondyloarthritis - enthesitis - enthesopathy - psoriatic arthritis - ankylosing spondylitis

Volltext

Referenzen

Literatur
1 Schweitzer ME, Resnick D. Enthesiopathy. In: Klippel JH, Dieppe PA. eds. Rheumatology. London, Mosby: 1994
2 McGonagle D, Khan MA, Marzo-Ortega H. et al. Enthesitis in spondyloarthropathy. Curr Opin Rheumatol 1999; 11 (04) 244-250.
3 Ball J. Enthesopathy of rheumatoid and ankylosing spondylitis. Ann Rheum Dis 1971; 30 (03) 213-223.
4 MacGregor AJ. Classification criteria for rheumatoid arthritis. Baillieres Clin Rheumatol 1995; 09 (02) 287-304.
5 Rudwaleit M, van der Heijde D, Landewe R. et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011; 70 (01) 25-31.
6 Rudwaleit M, van der Heijde D, Landewe R. et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009; 68 (06) 777-783.
7 Rudwaleit M, Haibel H, Baraliakos X. et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 2009; 60 (03) 717-727.
8 Taylor W, Gladman D, Helliwell P. et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54 (08) 2665-2673.
9 D’Agostino MA, Olivieri I. Enthesitis. Best Pract Res Clin Rheumatol 2006; 20 (03) 473-486.
10 Lehtinen A, Taavitsainen M, Leirisalo-Repo M. Sonographic analysis of enthesopathy in the lower extremities of patients with spondylarthropathy. Clin Exp Rheumatol 1994; 12 (02) 143-148.
11 McGonagle D, Marzo-Ortega H, O’Connor P. et al. The role of biomechanical factors and HLA-B27 in magnetic resonance imaging-determined bone changes in plantar fascia enthesopathy. Arthritis Rheum 2002; 46 (02) 489-493.
12 McGonagle D, Emery P. Enthesitis, osteitis, microbes, biomechanics, and immune reactivity in ankylosing spondylitis. J Rheumatol 2000; 27 (10) 2302-2304.
13 McGonagle D, Stockwin L, Isaacs J, Emery P. An enthesitis based model for the pathogenesis of spondyloarthropathy. additive effects of microbial adjuvant and biomechanical factors at disease sites. J Rheumatol 2001; 28 (10) 2155-2159.
14 Olivieri I, Scarano E, Ciancio G. et al. Lateral epicondylitis with marked soft tissue swelling in spondyloarthritis. Clin Rheumatol 2004; 23 (03) 275-276.
15 McGonagle D, Marzo-Ortega H, O’Connor P. et al. Histological assessment of the early enthesitis lesion in spondyloarthropathy. Ann Rheum Dis 2002; 61 (06) 534-537.
16 Ball J. The enthesopathy of ankylosing spondylitis. Br J Rheumatol 1983; 22 (4 Suppl 2): 25-28.
17 Mander M, Simpson JM, McLellan A. et al. Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis 1987; 46 (03) 197-202.
18 Dawes PT, Sheeran TP, Beswick EJ, Hothersall TE. Enthesopathy index in ankylosing spondylitis. Ann Rheum Dis 1987; 46 (09) 717.
19 Gorman JD, Sack KE, Davis Jr JC. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002; 346 (18) 1349-1356.
20 Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A. et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003; 62 (02) 127-132.
21 van der Heijde D, Kivitz A, Schiff MH. et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54 (07) 2136-2146.
22 Brandt J, Khariouzov A, Listing J. et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003; 48 (06) 1667-1675.
23 Braun J, Brandt J, Listing J. et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359 (9313): 1187-1193.
24 Maksymowych WP, Mallon C, Morrow S. et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis 2009; 68 (06) 948-953.
25 Landewe R, van Tubergen A. Clinical Tools to Assess and Monitor Spondyloarthritis. Current rheumatology reports 2015; 17 (07) 47.
26 Resnick D, Feingold ML, Curd J. et al. Calcaneal abnormalities in articular disorders. Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and Reiter syndrome. Radiology 1977; 125 (02) 355-366.
27 Resnick D, Niwayama G. Entheses and enthesopathy. Anatomical, pathological, and radiological correlation. Radiology 1983; 146 (01) 1-9.
28 Balint PV, Kane D, Wilson H. et al. Ultrasonography of entheseal insertions in the lower limb in spondyloarthropathy. Ann Rheum Dis 2002; 61 (10) 905-910.
29 Genc H, Cakit BD, Tuncbilek I, Erdem HR. Ultrasonographic evaluation of tendons and enthesal sites in rheumatoid arthritis: comparison with ankylosing spondylitis and healthy subjects. Clin Rheumatol 2005; 24 (03) 272-277.
30 Newman JS, Adler RS. Power Doppler Sonography: Applications in Musculoskeletal Im-aging. Seminars in musculoskeletal radiology 1998; 02 (03) 331-340.
31 Koski JM, Saarakkala S, Helle M. et al. Power Doppler ultrasonography and synovitis: correlating ultrasound imaging with histopathological findings and evaluating the performance of ultrasound equipments. Ann Rheum Dis 2006; 65 (12) 1590-1595.
32 D’Agostino MA, Said-Nahal R, Hacquard-Bouder C. et al. Assessment of peripheral enthesitis in the spondylarthropathies by ultrasonography combined with power Doppler: a cross-sectional study. Arthritis Rheum 2003; 48 (02) 523-533.
33 de Miguel E, Cobo T, Munoz-Fernandez S. et al. Validity of enthesis ultrasound assessment in spondyloarthropathy. Ann Rheum Dis 2009; 68 (02) 169-174.
34 Kiris A, Kaya A, Ozgocmen S, Kocakoc E. Assessment of enthesitis in ankylosing spondylitis by power Doppler ultrasonography. Skeletal Radiol 2006; 35 (07) 522-528.
35 Sieper J, van der Heijde D, Landewe R. et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis 2009; 68 (06) 784-788.
36 Erdem CZ, Sarikaya S, Erdem LO. et al. MR imaging features of foot involvement in ankylosing spondylitis. European journal of radiology 2005; 53 (01) 110-119.
37 Barozzi L, Olivieri I, De Matteis M. et al. Seronegative spondylarthropathies: imaging of spondylitis, enthesitis and dactylitis. European journal of radiology 1998; 27 (Suppl 1): S12-S17.
38 McGonagle D. Imaging the joint and enthesis: insights into pathogenesis of psoriatic arthritis. Ann Rheum Dis 2005; 64 (Suppl 2): ii58-60.
39 Eshed I, Bollow M, McGonagle DG. et al. MRI of enthesitis of the appendicular skeleton in spondyloarthritis. Ann Rheum Dis 2007; 66 (12) 1553-1559.
40 Tan AL, McGonagle D. Imaging of seronegative spondyloarthritis. Best Pract Res Clin Rheumatol 2008; 22 (06) 1045-1059.
41 McGonagle D, Gibbon W, O’Connor P. et al. Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum 1998; 41 (04) 694-700.
42 McGonagle D, Gibbon W, Emery P. Classification of inflammatory arthritis by enthesitis. Lancet 1998; 352 (9134): 1137-1140.
43 Klang E, Aharoni D, Hermann KG. et al. Magnetic resonance imaging of pelvic entheses-a systematic comparison between short tau inversion recovery (STIR) and T1-weighted, contrast-enhanced, fatsaturated sequences. Skeletal Radiol 2014; 43 (04) 499-505.
44 Poggenborg RP, Eshed I, Ostergaard M. et al. Enthesitis in patients with psoriatic arthritis, axial spondyloarthritis and healthy subjects assessed by ‘head-to-toe’ whole-body MRI and clinical examination. Ann Rheum Dis. 2014
45 Eich W, Hauser W, Friedel E. et al. [Definition, classification and diagnosis of fibromyalgia syndrome]. Schmerz 2008; 22 (03) 255-266.
46 Appel H, Kuhne M, Spiekermann S. et al. Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrow. Arthritis Rheum 2006; 54 (06) 1805-1813.
47 Zochling J, van der Heijde D, Burgos-Vargas R. et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65 (04) 442-452.
48 van der Heijde D, Baraf HS, Ramos-Remus C. et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 2005; 52 (04) 1205-1215.
49 Ritchlin CT, Kavanaugh A, Gladman DD. et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009; 68 (09) 1387-1394.
50 Haibel H, Fendler C, Listing J. et al. Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial. Ann Rheum Dis 2014; 73 (01) 243-246.
51 Gadzhinova LD, Shubin SV, Mach ES. et al. [The local therapy of enthesitis and bursitis of the calcaneal area in seronegative spondylarthritis]. Terapevticheskii arkhiv 1997; 69 (05) 47-49.
52 Haibel H, Brandt HC, Song IH. et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis 2007; 66 (03) 419-421.
53 Haibel H, Rudwaleit M, Braun J, Sieper J. Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis 2005; 64 (01) 124-126.
54 Song IH, Hermann K, Haibel H. et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 2011; 70 (04) 590-596.
55 Dougados M, Combe B, Braun J. et al. A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. Ann Rheum Dis 2010; 69 (08) 1430-1435.
56 Mease PJ, Ory P, Sharp JT. et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009; 68 (05) 702-709.
57 Carron P, Varkas G, Cypers H. et al. Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA study. Ann Rheum Dis 2017; 76 (08) 1389-1395.
58 McInnes IB, Mease PJ, Ritchlin CT. et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology (Oxford) 2017; 56 (11) 1993-2003.
59 van der Heijde D, Gladman DD, Kishimoto M. et al. Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1). J Rheumatol. 2017
60 Araujol EG, Englbrecht M, Hoepken S. et al. Ustekinumab Is Superior to TNF Inhibitor Treatment in Resolving Enthesitis in Psa Patients with Active Enthesitis- Results from the Enthesial Clearance in Psoriatic Arthritis Study [Abstract]. Arthritis Rheum. 69. ((suppl 10)) 2017
61 Mease P, Hall S, FitzGerald O. et al. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. N Engl J Med 2017; 377 (16) 1537-1550.
62 Mease P, Kellner H, Morita A. et al. Efficacy and Safety Results from a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor, in Patients with Active Psoriatic Arthritis [abstract]. Arthritis Rheum. 2017 69. (suppl 10).